Zacks Investment Research upgraded shares of CAMBREX CORP (CBM) from UNDERPERFORM to NEUTRAL on June 27, 2013, with a target price of $14.30.
Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives pharmaceutical intermediates organic intermediates performance enhancers and polymer systems.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CAMBREX CORP (CBM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment